SCHEMBL25819527

SCHEMBL25819527

Cc1ccc(-c2cccc(O)n2)c(OCc2ccccc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.43
HSD17B10 Q99714 1/20 0.41
MAPK1 P28482 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
LMNA P02545 2/20 0.39
TSHR P16473 2/20 0.39
HTT P42858 1/20 0.39
MAPT P10636 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GBA1 P04062 1/20 0.38
SQOR Q9Y6N5 1/20 0.38
GRM5 P41594 1/20 0.38
CNR1 P21554 3/20 0.37
KDM4E B2RXH2 1/20 0.37
HRH4 Q9H3N8 1/20 0.36
CYP1A2 P05177 1/20 0.36
PTGS1 P23219 1/20 0.36
SLC6A2 P23975 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30475469 0.85 GRM5 (0.41) L3MBTL1MAPK1ALDH1A1HPGDLMNA
SCHEMBL25824951 0.85 GRM5 (0.41) L3MBTL1MAPK1ALDH1A1HPGDLMNA
SCHEMBL25819126 0.80 L3MBTL1 (0.47) L3MBTL1MAPK1ALDH1A1HPGDLMNA
SCHEMBL25819100 0.79 L3MBTL1 (0.43) L3MBTL1MAPK1ALDH1A1HPGDLMNA
SCHEMBL25819197 0.75 L3MBTL1 (0.44) L3MBTL1MAPK1ALDH1A1HPGDMAPT
SCHEMBL27301730 0.74 L3MBTL1 (0.56) L3MBTL1MAPK1ALDH1A1HPGDLMNA
SCHEMBL26044686 0.73 MEN1 (0.48) L3MBTL1ALDH1A1LMNAMAPTSQOR
SCHEMBL26043793 0.73 MAPT (0.47) L3MBTL1TSHRMAPTSQORCNR1
SCHEMBL26043794 0.73 L3MBTL1 (0.46) L3MBTL1TSHRSQORCNR1
SCHEMBL25935014 0.73 GABRG2 (0.49) L3MBTL1SQORCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 L3MBTL1 964/4885HSD17B10 2913/4885MAPK1 1633/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 L3MBTL1 2040/4885HSD17B10 3131/4885MAPK1 1101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.